Objectives: To determine the CTCL response rate and safety of O6BG/BCNU when given biweekly as two consecutive daily doses, and to determine the laboratory correlates of clinical response and drug efficacy based upon several surrogate marker studies including the examination of O6-alkylguanine DNA alkyltransferase (AGT) activity in CTCL lesions.
Eligibility: Eligibility criteria include but are not limited to the following: diagnosis of CTCL stages IA, IB, or IIA by histopathology and immunohistochemistry; age > 18 years; must have failed at least one conventional treatment for CTCL other than topical corticosteroids; and must have cutaneous disease that is amenable to biopsy and must be willing to undergo several sequential biopsies.
University Hospitals Case Medical Center
Deptartment of Dermatology
Kevin D. Cooper, MD